Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey Conix, are you on Stocktwits by any chance? Are you holding Vaxart or Mullen?
IMO. Nasrat will be the only winner here at the end. I sold more than half of mine when Carter left. 11 years is more than enough of waiting. I’m still holding some shares just to go back here from time to time and check on it. I still see the same guy pumping and post the same old lines. I’m glad I got all my money back and more when I used that money invested in Moderna. Good luck my friend. Re-do your DD!!!
Nothing new here Ryan. It’s going to be another drop after the CC as always. It’s sad but true.
I feel you Snup. Good luck my friend.
I sold 1 million shares which was about 1/2 of my shares at .09s back then. I can buy back and double it AT ANYTIME I WANT TO. That I’ll get me over 3 million shares now. Gotta play this game boy!!! Nasrat? LOL
Great post. Thanks Doc.!
Dude ELTP is not in vaccine business. LOL
What made you excited? I see no news!
What am I missing? Is there news?
I feel you snup. Good luck my old drunken friend!!!
Hey conix, Good to see you here. What does the Chart say? TIA
How high do you think the PPS goes up tomorrow?
Repost Today’s Awesome News!!!
Bio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program
5/6/21, 4:15 PM
BRYAN, Texas, May 06, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection.
IBIO-201, the Company’s vaccine candidate combining antigens derived from the spike protein (“S protein”) fused with iBio’s patented LicKM™ booster molecule, recently completed IND-enabling toxicology studies. The studies identified no adverse effects at low or high doses.
“Combined with data from previous immune-response studies, these pathology results help demonstrate the potential value of LicKM as a useful tool in our vaccine development toolbox,” said Tom Isett, Chairman and CEO of iBio.
The Company also reported on development of IBIO-202, a subunit vaccine candidate that targets the nucleocapsid protein (“N protein”) of SARS-CoV-2. N proteins of many coronaviruses are highly immunogenic and are expressed abundantly during infection. In addition, the N protein is more highly conserved than the S protein, and therefore new viral variants may be less likely to escape vaccine protection.
"In light of the successful global roll-out of COVID-19 vaccines targeting the S protein and the emergence of variant strains of the disease, we decided to focus our efforts on the continued development of IBIO-202 as a differentiated vaccine candidate,” commented Mr. Isett. “The COVID-19 vaccine space remains highly competitive, with multiple approved vaccines in use in many countries. Nevertheless, various unmet needs remain, including: vaccines that provide broader protection against variants; the potential requirement for annual vaccine boosters; vaccines that do not require significant cold chain management; vaccines with alternative routes of administration; pan-coronavirus vaccines; and wider vaccine availability in developing countries," said Mr. Isett.
Using its plant-based FastPharming® System, iBio has successfully expressed N protein antigens and has initiated both intramuscular and intranasal preclinical studies to identify favorable antigen-adjuvant combinations. Results are expected in early Q1 FY2022. iBio recently filed four provisional patent applications with the U.S. Patent and Trademark Office in support of the IBIO-202 program.
“Immunization with more conserved sequences, such as the N protein, is expected to generate T-cells that could clear spike protein variant viruses in addition to the original virus,” said Martin Brenner, DVM. Ph.D., iBio’s CSO. “The N protein strategy of IBIO-202 is complementary to existing first-generation, S protein-directed vaccines and may be suitable as a more universal coronavirus vaccine.”
In parallel with the development of IBIO-202, the Company continues to evaluate the potential of a multi-subunit vaccine candidate to further increase vaccine protection from variants by targeting two or more important elements of the SARS-CoV-2 virus.
Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)
LOL ...
Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans
Mentioned: VXRT
Nearly 19 million Americans who will decline vaccines would get vaccinated if they had a pill option, Vaxart's poll finds
Seven in 10 said they would prefer a pill over an injection
Nearly 19 million more American adults - about a third of those now refusing to get vaccinated - would get vaccinated if they could take a pill instead of getting a shot, according to a poll conducted by Quadrant Strategies and commissioned by Vaxart, Inc.
The survey found that 23% of respondents said they do not plan to get vaccinated but nearly a third of them said they would if the vaccine were available as a pill instead of by a needle injection.
The results suggest that about half of the additional vaccinated group would be drawn from minority populations, communities that have disproportionately not been vaccinated. The Centers for Disease Control and Prevention report only 12% of Hispanics, 9% of Blacks, and 6% of Asians have received vaccines as of April 21, 2021.
"Vaccinating another 19 million American adults may help the US reach herd immunity. The public health and societal implications of an oral Covid-19 vaccine could be both broad and profound," said Vaxart chief executive officer Andrei Floroiu.
"This poll suggests as many as an additional 4 million Black, 3 million rural, 2 million Hispanic and 1 and a half million Asian Americans would take a pill Covid-19 vaccine. That provides an important path to reducing healthcare inequity in this country and to alleviating the disproportionate impact Covid-19 has had on predominantly minority and rural communities," Floroiu said.
"It is not surprising that seven in 10 Americans prefer a pill to getting stuck with a needle," Vaxart chief science officer Sean Tucker said. "Needle injections present a barrier to getting people vaccinated and we have a solution that we believe will be effective and would allow people to avoid injections they don't want to have."
Nearly a quarter of respondents said they are afraid of needles and that fear is found among all groups.
"We need to tear down this barrier to vaccinating more Americans. A pill option taken at home on their own time raises the number of Americans likely to get a Covid-19 vaccine in a material way," Floroiu said.
The national survey of 1,500 Americans over the age of 18, conducted by Quadrant Strategies between March 17 and 24, also found that:
This survey's findings come as the government has reported newer and more variants of Covid-19 in the United States.
Vaxart recently completed the Phase 1 study of its oral tablet coronavirus vaccine:
Survey Methodology
Quadrant Strategies conducted an online national survey of 1,500 Americans 18 and older between March 17 and 24, 2021. The margin of error is +/- 3%. Quadrant Strategies is based in Washington, D.C.
Over 2.2 million shares on the bid now ...LOL
Totally agree. No more crying!
Exactly. Haven’t seen that kind of large bid in a long time. Hit that and we will be over 2 million shares today!
2,483,675 shares on the bid.
Why did you say there’s a blackout period?
We’re in the 3rd week of April...LOL
Will GSAT get some?
It says 30 days not 6 months!!!
Sure sounds very interesting and I hope we will get there soon. Any which way will you can Nasrat!
Of course I know what I own. The stock that keep bleeding and in need for some bandages...
Let’s hope it holds and doesn’t go under $1!!
For a profitable company, I say Elite is very secure vs. that company.
What are you saying?
“currently listed on the OTC bulletin board, with plans for a NASDAQ uplisting in the short to medium term.”
This is what most of us are waiting for!
Maybe LOL
Yup. 15,000,000
I might exit before that LOL.
Maybe before the weekend. I believe!!!
Ouch. They don’t think much of him.
NONE. He sucks, IMO
Agree with you again.
Good point Ryan! Carter sucks anyway!
True...